Antibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance

High antibiotic resistance frequencies have become a major public health issue. The decrease in new antibiotics' production, combined with increasing frequencies of multi-drug resistant (MDR) bacteria, cause substantial limitations in treatment options for some bacterial infections. To diminish overall resistance, and especially the occurrence of bacteria that are resistant to all antibiotics, certain drugs are deliberately scarcely used—mainly when other options are exhausted. We use a mathematical model to explore the efficiency of such antibiotic restrictions. We assume two commonly used drugs and one restricted drug. The model is examined for the mixing strategy of antibiotic prescription, in which one of the drugs is randomly assigned to each incoming patient. Data obtained from Rabin medical center, Israel, is used to estimate realistic single and double antibiotic resistance frequencies in incoming patients. We find that broad usage of the hitherto restricted drug can reduce the number of incorrectly treated patients, and reduce the spread of bacteria resistant to both common antibiotics. Such double resistant infections are often eventually treated with the restricted drug, and therefore are prone to become resistant to all three antibiotics. Thus, counterintuitively, a broader usage of a formerly restricted drug can sometimes lead to a decrease in the emergence of bacteria resistant to all drugs. We recommend re-examining restriction of specific drugs, when multiple resistance to the relevant alternative drugs already exists.

[1]  Carl T. Bergstrom,et al.  The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S Bonhoeffer,et al.  Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Milatovic,et al.  Development of resistance during antibiotic therapy , 1987, European Journal of Clinical Microbiology.

[4]  T. Day,et al.  A theoretical examination of the relative importance of evolution management and drug development for managing resistance , 2014, Proceedings of the Royal Society B: Biological Sciences.

[5]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[6]  S. Bonhoeffer,et al.  On Being the Right Size: The Impact of Population Size and Stochastic Effects on the Evolution of Drug Resistance in Hospitals and the Community , 2011, PLoS Pathogens.

[7]  M. D. Kraker,et al.  The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  Marc Lipsitch,et al.  Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy , 2009, PLoS medicine.

[9]  Alexandro Rodríguez-Rojas,et al.  Antibiotics and antibiotic resistance: a bitter fight against evolution. , 2013, International journal of medical microbiology : IJMM.

[10]  U. Obolski,et al.  Implications of stress-induced genetic variation for minimizing multidrug resistance in bacteria , 2012, BMC Medicine.

[11]  V. Miriagou,et al.  Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  G Sherman,et al.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.

[13]  A. P. Williams,et al.  The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. , 2013, The Lancet. Infectious diseases.

[14]  Brad Spellberg,et al.  The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  L. Martínez-Martínez,et al.  Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. , 2007, The Journal of antimicrobial chemotherapy.

[16]  F. Baquero,et al.  Importance of Local Variations in Antibiotic Consumption and Geographical Differences of Erythromycin and Penicillin Resistance in Streptococcus pneumoniae , 2002, Journal of Clinical Microbiology.

[17]  F. Saulnier,et al.  Multiple-drug–resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome* , 2006, Critical care medicine.

[18]  M.X. Mashford Antibiotic Guidelines , 1985 .

[19]  K. Soares-Weiser,et al.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. , 2006, The Cochrane database of systematic reviews.

[20]  M. Leeb A shot in the arm , 2004 .

[21]  M. Lipsitch,et al.  Antibiotic resistance--the interplay between antibiotic use in animals and human beings. , 2003, The Lancet. Infectious diseases.

[22]  S. Cosgrove,et al.  Clinical and economic burden of antimicrobial resistance , 2008, Expert review of anti-infective therapy.

[23]  N. Woodford,et al.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.

[24]  O. Berg,et al.  Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. , 2000, Science.

[25]  B. Cooper,et al.  Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Spellberg,et al.  The FDA Reboot of Antibiotic Development , 2013, Antimicrobial Agents and Chemotherapy.

[27]  Carl T. Bergstrom,et al.  Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Andrews BSAC standardized disc susceptibility testing method. , 2001, The Journal of antimicrobial chemotherapy.

[29]  J. Mcgowan Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. , 2006, The American journal of medicine.

[30]  Ronald N. Jones,et al.  Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. , 2005, Diagnostic microbiology and infectious disease.

[31]  Yehuda Carmeli,et al.  Multidrug-Resistant Pseudomonas aeruginosa: Risk Factors and Clinical Impact , 2006, Antimicrobial Agents and Chemotherapy.

[32]  K. Soares-Weiser,et al.  Beta lactam monotherapy versus beta lactam‐aminoglycoside combination therapy for treating sepsis , 2001 .

[33]  Sebastian Bonhoeffer,et al.  Cycling Empirical Antibiotic Therapy in Hospitals: Meta-Analysis and Models , 2014, PLoS pathogens.

[34]  J. Garau,et al.  Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. , 2007, International journal of antimicrobial agents.

[35]  Hajo Grundmann,et al.  Mortality and Hospital Stay Associated with Resistant Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in Europe , 2011, PLoS medicine.

[36]  P. Tamma,et al.  Pediatric Antimicrobial Susceptibility Trends across the United States , 2013, Infection Control & Hospital Epidemiology.

[37]  U. Obolski,et al.  Resistance profiles of coagulase-negative staphylococci contaminating blood cultures predict pathogen resistance and patient mortality. , 2014, The Journal of antimicrobial chemotherapy.

[38]  Sebastian Bonhoeffer,et al.  Informed Switching Strongly Decreases the Prevalence of Antibiotic Resistance in Hospital Wards , 2011, PLoS Comput. Biol..

[39]  S. Piscitelli,et al.  Development of Resistance During Antimicrobial Therapy: A Review of Antibiotic Classes and Patient Characteristics in 173 Studies , 1995, Pharmacotherapy.

[40]  Diarmaid Hughes,et al.  Antibiotic resistance and its cost: is it possible to reverse resistance? , 2010, Nature Reviews Microbiology.

[41]  Stephan Harbarth,et al.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. , 2003, The American journal of medicine.

[42]  H. Goossens,et al.  Antibiotic resistance—the need for global solutions , 2013, BDJ.

[43]  M. Lipsitch,et al.  The analysis of hospital infection data using hidden Markov models. , 2004, Biostatistics.

[44]  张静,et al.  Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening , 2015 .

[45]  J. Andrews BSAC standardized disc susceptibility testing method , 2001 .

[46]  R. Anderson,et al.  Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Blot,et al.  Comment on: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. , 2007, The Journal of antimicrobial chemotherapy.

[48]  Michele L. Joyner,et al.  Modeling the effects of introducing a new antibiotic in a hospital setting: A case study. , 2012, Mathematical biosciences and engineering : MBE.

[49]  J. Mcgowan Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. , 2006, American journal of infection control.